Highlights
- •Expert groups (6) on selection and validation of outcome measures in DM1.
- •Somnolence/Fatigue/Apathy new Special Interest Group.
- •Ongoing research projects to document metrological properties of several instruments.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Neuromuscular DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- OMERACT: an international initiative to improve outcome measurement in rheumatology.Trials. 2007; 8: 38
- Foundations of clinical research: applications to practice.2nd ed. Prentice Hall Health, Upper Saddle River (NJ)2000
- Tau exon 2 responsive elements deregulated in myotonic dystrophy type I are proximal to exon 2 and synergistically regulated by MBNL1 and MBNL2.Biochim Biophys Acta. 2014; 1842: 654-664
- MBNL1 gene variants as modifiers of disease severity in myotonic dystrophy type 1.J Neurol. 2013; 260: 998-1003
- Activity rating scales in adult muscle disease: how well do they actually measure?.Muscle Nerve. 2014; 50: 24-33
- Activity rating scales in adult muscle disease: what do they actually measure?.Muscle Nerve. 2014; 50: 14-23
- The COSMIN checklist for assessing the methodological quality of studies on measurement properties of health status measurement instruments: an international Delphi study.Qual Life Res. 2010; 19: 539-549
- Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.Muscle Nerve. 2014; 49: 906-914
- Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).Neurology. 2012; 79: 348-357
- Guidance for industry – patient-reported outcome measures: use in medical product development to support labeling claims.Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research. Center for Devices and Radiological Health, Silver Spring (MD)2009
- Identifying high impact symptoms and issues in congenital and juvenile myotonic dystrophy.Neurology. 2012; 78: P05.186
- Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL).Neurology. 2007; 68: 1051-1057
- The Individualized Neuromuscular Quality of Life Questionnaire (INQoL); Cultural translation and psychometric validation for the Dutch population.Muscle Nerve. 2014;
- Serbian validation of the Individualized Neuromuscular Quality of Life Questionnaire (INQoL) in adults with myotonic dystrophy type 1.J Neurol Res. 2011; 1: 153-160
- Italian validation of INQoL, a quality of life questionnaire for adults with muscle diseases.Eur J Neurol. 2010; 17: 1178-1187
- Validation of the Individualised Neuromuscular Quality of Life for the USA with comparison of the impact of muscle disease on those living in USA versus UK.Health Qual Life Outcomes. 2011; 9: 114
- The neurology quality-of-life measurement initiative.Arch Phys Med Rehabil. 2011; 92: S28-36
- The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008.J Clin Epidemiol. 2010; 63: 1179-1194
- NIH toolbox for assessment of neurological and behavioral function.Neurology. 2013; 80: S2-6
- Quality of life measures in epilepsy: how well can they detect change over time?.Neurology. 2000; 54: 1822-1827
- Generic and disease-specific measures in assessing health status and quality of life.Med Care. 1989; 27: S217-32
- Factors of importance when evaluating quality of life in clinical trials.Control Clin Trials. 1990; 11: 169-179
- Report of the first Outcome Measures in Myotonic Dystrophy type 1 (OMMYD-1) international workshop: Clearwater, Florida, November 30, 2011.Neuromuscul Disord. 2013; 23: 1056-1068
- The endurance shuttle walk: a new field test for the assessment of endurance capacity in chronic obstructive pulmonary disease.Thorax. 1999; 54: 213-222
- A 30-s chair-stand test as a measure of lower body strength in community-residing older adults.Res Q Exerc Sport. 1999; 70: 113-119
- A new test of dynamic standing balance for stroke patients: reliability, validity and comparison with healthy elderly.Physiother Can. 1996; 48: 257-262
- Perceived functioning and disability in adults with myotonic dystrophy type 1: a survey according to the International Classification of Functioning, Disability and Health.J Rehabil Med. 2009; 41: 512-520
- Évaluation de la capacité fonctionnelle chez des patients atteints de dystrophie myotonique de type 1. Mémoire de maîtrise.(Programme de médecine expérimentale, Université Laval: Quebec)2012
- Lower limb muscle impairment in myotonic dystrophy type 1: the need for better guidelines.Muscle Nerve. 2014;
- Myotonic dystrophy: clinical assessment of muscular disability in an isolated population with presumed homogeneous mutation.Neurology. 1992; 42: 203-208
- Quantitative motor assessment in myotonic dystrophy.Can J Neurol Sci. 2003; 30: 129-136
- Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.Neurology. 2001; 56: 336-340
- Profiles of neuromuscular diseases. Myotonic dystrophy.Am J Phys Med Rehabil. 1995; 74: S104-16
- A 10-year study of mortality in a cohort of patients with myotonic dystrophy.Neurology. 1999; 52: 1658-1662
- Falls and stumbles in myotonic dystrophy.J Neurol Neurosurg Psychiatry. 2006; 77: 393-396
- Cognitive impairment in adult myotonic dystrophies: a longitudinal study.Neurol Sci. 2007; 28: 9-15
- CTG-repeat length in distal and proximal leg muscles of symptomatic and non-symptomatic patients with myotonic dystrophy: relation to muscle strength and degree of histopathological abnormalities.Eur J Neurol. 1999; 6: 341-346
- Myotonic dystrophy: practical issues relating to assessment of strength.J Neurol Neurosurg Psychiatry. 2006; 77: 1282-1283
- A longitudinal physical profile assessment of skeletal muscle manifestations in myotonic dystrophy.Clin Rehabil. 1999; 13: 64-73
- Deterioration of motor function in myotonic dystrophy and hereditary motor and sensory neuropathy.Scand J Rehabil Med. 1995; 27: 59-64
- Patient registries and Trial Readiness in Myotonic Dystrophy – TREAT-NMD/Marigold International Workshop Report.Neuromuscul Disord. 2009; 19: 860-866
- Activity limitations in patients with neuromuscular disorders: a responsiveness study of the ACTIVLIM questionnaire.Neuromuscul Disord. 2009; 19: 99-103
- The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study.BMC Musculoskelet Disord. 2010; 11: 72
- Reliable surrogate outcome measures in multicenter clinical trials of Duchenne muscular dystrophy.Muscle Nerve. 2007; 35: 36-42
- Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7.J Rheumatol. 2005; 32: 2488-2495
- Hypersomnolence in myotonic dystrophy: demonstration of sleep onset REM sleep.J Neurol Neurosurg Psychiatry. 1995; 58: 512-513
- Myotonic dystrophy.3rd ed. WB Saunders, London2001 (436 p)
- Hypersomnia in dystrophia myotonica.J Neurol Neurosurg Psychiatry. 1961; 24: 173-175
- Disturbances of wakefulness, sleep and respiratory function in Steinert's disease.Rev Neurol (Paris). 1977; 133: 255-277
- A polysomnographic study of daytime sleepiness in myotonic dystrophy type 1.J Neurol Neurosurg Psychiatry. 2009; 80: 642-646
- Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I.J Neurol Neurosurg Psychiatry. 2005; 76: 1406-1409
- Fatigue in neurological disorders.Lancet. 2004; 363: 978-988
- Myotonia atrophica (dystrophica myotonica).Deutsche Ztschr. 1916; 55: 242-248
- Mental changes in and social conditions of patients with dystrophica myotonica.in: Myotonia: Thomsen's disease (myotonica congenita), paramyotonia, and dystrophica myotonica. Aarhuus Stiftsborgtrykkerie A/S, Danmark1948: 154-161
- Dystrophia myotonica and related disorders.Charles C. Thomas, Springfield (IL)1963
- Apathy and hypersomnia are common features of myotonic dystrophy.J Neurol Neurosurg Psychiatry. 1998; 64: 510-515
- Does abnormal neuronal excitability exist in myotonic dystrophy? II. Effects of the antiarrhythmic drug hydroquinidine on apathy and hypersomnia.Neurol Sci. 2000; 21: 81-86
- Impact des facteurs génétiques, fonctionnel, psychopathologiques et neuropsychologiques dans l'adaptation à la dystrophie myotonique de Steinert. [Impact of clinical, functional, psychopathological and neuropsychological factors on the adaptation to the Steinert myotonic dystrophy].(Université Paris 8 – Vincenne-Saint-Denis. p. 246)2010
- Fatigue and daytime sleepiness scale in myotonic dystrophy type 1.Muscle Nerve. 2013; 47: 89-95
- The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus.Arch Neurol. 1989; 46: 1121-1123
- Sleep complaints in patients with myotonic dystrophy.J Sleep Res. 2004; 13: 95-100
- A new method for measuring daytime sleepiness: the Epworth sleepiness scale.Sleep. 1991; 14: 540-545
- Principles of good practice for the translation and cultural adaptation process for Patient-Reported Outcomes (PRO) measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.Value Health. 2005; 8: 94-104
Article info
Publication history
Published online: January 27, 2015
Received:
December 19,
2014
Identification
Copyright
© 2015 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
